Optimization of Dalbavancin in Patients with Hepatic or Renal Impairment

• 作者: Jingyi Zhao Jiuli Hu Junhui Hu Xu Xiao Yanwu Zhao Ying Wang Yinhui Yao
• 来源期刊: 药理与制药(英文)
• 学科: 医学
• 关键词: Mote Carlo SIMULATION DALBAVANCIN HEPATIC IMPAIRMENT RENAL IMPAIRMENT
• 年，卷（期）: ylyzyyw,（2）
• 页码范围: 29-37
• 页数: 9页
• 分类号: R97

摘要

Dalbavancin is a novel semi-synthetic glycopeptide antibiotic. In this study, we aimed to optimize the dosage regimen of dalbavancin in patients with hepatic or renal impairment by Mote Carlo simulation. Pharmacokinetic parameters and microbiological data were collected about dalbavancin. 10,000 patients with renal or hepatic impairment analyzed by Crystal Ball to calculate probability of target attainment (PTA) and cumulative fraction of response (CFR). We found that all bacterial PTA and CFR were more than 90% for dalbavancin in patients with hepatic or renal impairment, except for Enterococcus faecium. There is no need to adjust the dosage regimen of dalbavancin in patients with hepatic or renal impairment.